BOSTON--(BUSINESS WIRE)--BPGbio, Inc., a leading biology-first, AI-powered clinical-stage biopharma company focused on mitochondrial biology and protein homeostasis, today announced that it will present three scientific posters at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting, taking place November 6-10, 2024, in Houston, Texas.

波士顿--（商业新闻短讯）--BPGbio，Inc.，一家领先的生物学第一，人工智能驱动的临床阶段生物制药公司，专注于线粒体生物学和蛋白质稳态，今天宣布，它将在2024年11月6日至10日在德克萨斯州休斯顿举行的癌症免疫治疗学会（SITC）2024年会上展示三张科学海报。

The posters will highlight the latest research on the company’s drug candidates BPM31510 and BRG399 in the immuno-oncology space, providing further validation and paving the way for new potential therapeutic strategies in cancer treatment..

海报将重点介绍该公司候选药物BPM31510和BRG399在免疫肿瘤学领域的最新研究，为癌症治疗中新的潜在治疗策略提供进一步的验证和铺平道路。。

In the first study, titled “The Anti-tumor Response of BPM31510 is Associated with Immune Cell Regulation in the Tumor Microenvironment,” researchers showed that BPM31510 significantly increases reactive oxygen species (ROS) levels in cancer cells, leading to cell death across multiple cancer types.

在第一项题为“BPM31510的抗肿瘤反应与肿瘤微环境中的免疫细胞调节有关”的研究中，研究人员表明BPM31510显着增加癌细胞中的活性氧（ROS）水平，导致多种癌症类型的细胞死亡。

They also identified that, BPM31510 can boost the activity of cytotoxic tumor-infiltrating lymphocytes and reduce markers of T cell exhaustion. This dual action gives it the potential to be especially effective in treating 'immunologically cold' tumors, such as glioblastoma and pancreatic cancer..

他们还发现，BPM31510可以增强细胞毒性肿瘤浸润淋巴细胞的活性，并减少T细胞耗竭的标志物。这种双重作用使其有可能在治疗“免疫性感冒”肿瘤（如胶质母细胞瘤和胰腺癌）方面特别有效。。

The second study, titled “BRG399, a Novel Oral Microtubule Binding Agent, Induces Tumor Regression and Immune Memory in an Orthotopic Glioblastoma Rat Model,” found that BRG399 treatment leads to glioblastoma tumor regression, with 100% survival in treated rats. BRG399 also induces an immune memory response, preventing the recurrence of tumors when surviving rats are re-challenged with glioma cancer cells..

第二项研究名为“BRG399，一种新型口服微管结合剂，在原位胶质母细胞瘤大鼠模型中诱导肿瘤消退和免疫记忆”，发现BRG399治疗导致胶质母细胞瘤肿瘤消退，治疗大鼠存活率为100%。BRG399还诱导免疫记忆反应，当存活的大鼠被神经胶质瘤癌细胞再次攻击时，可防止肿瘤复发。。

The third study, titled, “BRG399, a Novel Oral Microtubule Binding Agent, Exhibits Immune-Modulatory Properties Enhancing Anti-Tumor Responses,” showed that BRG399 alters the immune cell composition within the tumor microenvironment and blood. BRG399 also reduced markers of T cell exhaustion, suggesting that it can reinvigorate immune responses against tumors.

第三项研究题为“BRG399，一种新型口服微管结合剂，具有增强抗肿瘤反应的免疫调节特性”，表明BRG399改变了肿瘤微环境和血液中的免疫细胞组成。BRG399还减少了T细胞耗竭的标志物，表明它可以重新激活针对肿瘤的免疫应答。

These findings suggest that BRG399 should be further investigated as a potential component of cancer therapy, particularly when combined with immunotherapies, as it can both kill cancer cells and enhance immune activity..

这些发现表明，BRG399应作为癌症治疗的潜在组成部分进行进一步研究，特别是与免疫疗法结合使用时，因为它既可以杀死癌细胞，又可以增强免疫活性。。

“These compounds – BPM31510 and BRG399 – push the boundaries of what's possible in cancer therapy, showing that we can not only attack the tumor but also empower the body's immune system to keep fighting long after the treatment ends,” said Stephane Gesta, Ph.D., VP, Discovery and Translational Biology at BPGbio.

BPGbio发现与转化生物学副总裁斯蒂芬·盖斯塔博士说：“这些化合物——BPM31510和BRG399——突破了癌症治疗的可能界限，表明我们不仅可以攻击肿瘤，还可以增强人体免疫系统在治疗结束后长时间保持战斗力。”。

“As we advance BRG399 through preclinical trials and approach the completion of BPM31510's Phase 2b study, we will continue leveraging our NAi Interrogative Biology Platform to gain additional insight for exploring new therapeutic opportunities for other diseases.”.

“随着我们通过临床前试验推进BRG399并接近完成BPM31510的2b期研究，我们将继续利用我们的NAi询问生物学平台，获得更多见解，以探索其他疾病的新治疗机会。”。

Poster Presentation Details:

海报展示细节：

The Anti-Tumor Response of BPM31510 Is Associated with Immune Cell Regulation in the Tumor Microenvironment

BPM31510的抗肿瘤反应与肿瘤微环境中的免疫细胞调节有关

Date and Time: November 8, 2024, 1:00 p.m. CST

Date and Time: November 8, 2024, 1:00 p.m. CST

Location: Exhibit Halls A B, George R. Brown Convention Center, Houston, Texas

地点：德克萨斯州休斯顿乔治·R·布朗会议中心A、B展厅

Presenter: Maria-Dorothea Nastke, Ph.D.

主持人：Maria Dorothea Nastke博士。

Abstract Number: 1312

摘要编号：1312

BRG399, a Novel Oral Microtubule Binding Agent, Induces Tumor Regression and Immune Memory in an Orthotopic Glioblastoma Rat Model

新型口服微管结合剂BRG399在原位胶质母细胞瘤大鼠模型中诱导肿瘤消退和免疫记忆

Date and Time: November 9, 2024, 2:00 p.m. CST

Date and Time: November 9, 2024, 2:00 p.m. CST

Location: Exhibit Halls A B, George R. Brown Convention Center, Houston, Texas

地点：德克萨斯州休斯顿乔治·R·布朗会议中心A、B展厅

Presenter: Maria-Dorothea Nastke, Ph.D.

主持人：Maria Dorothea Nastke博士。

Abstract Number: 1313

摘要编号：1313

BRG399, a Novel Oral Microtubule-Binding Agent, Exhibits Immune-Modulatory Properties Enhancing Anti-Tumor Responses

BRG399是一种新型口服微管结合剂，具有增强抗肿瘤反应的免疫调节特性

Date and Time: November 9, 2024, 3:00 p.m. CST

Date and Time: November 9, 2024, 3:00 p.m. CST

Location: Exhibit Halls A B, George R. Brown Convention Center, Houston, Texas

地点：德克萨斯州休斯顿乔治·R·布朗会议中心A、B展厅

Presenter: Kaila Bennett, Ph.D.

主讲人：凯拉·贝内特博士。

Abstract Number: 1284

摘要编号：1284

About BPM31510

关于BPM31510

BPM31510 is BPGbio’s lead candidate in late-stage development for glioblastoma multiforme (GBM) and pancreatic cancer. The compound has demonstrated a tolerable safety profile and shown potential clinical benefit in both populations. The mechanism of action of BPM31510 was first validated by data from BPGbio’s NAi Interrogative Biology platform, which suggested that there is a hallmark shift in the tumor microenvironment (TME) induced by BPM31510 which modulates mitochondrial oxidative phosphorylation in highly aggressive tumors.

BPM31510是BPGbio在多形性胶质母细胞瘤（GBM）和胰腺癌晚期发展中的主要候选者。该化合物已显示出可耐受的安全性，并在两种人群中均显示出潜在的临床益处。BPM31510的作用机制首先通过BPGbio的NAi询问生物学平台的数据进行了验证，这表明BPM31510诱导的肿瘤微环境（TME）发生了标志性变化，可调节高度侵袭性肿瘤中的线粒体氧化磷酸化。

BPGbio has received FDA's Rare Pediatric Disease Designation for BPM31510IV for primary CoQ10 deficiency and BPM31510T for Epidermolysis Bullosa (EB) ..

BPGbio已获得FDA罕见儿科疾病指定，用于原发性辅酶Q10缺乏症的BPM31510IV和用于大疱性表皮松解症（EB）的BPM31510T。。

About BRG399

关于BRG399

BRG399 is a BPGbio-developed candidate being studied for its therapeutic potential as a treatment for solid and liquid tumor cancers as well as diseases associated with neutrophil-driven inflammation. This experimental drug, a first-in-class, anti-tubulin agent with broad-spectrum anti-cancer activity and favorable pharmacological properties including oral bioavailability for clinical testing.

BRG399是BPGbio开发的候选药物，正在研究其作为治疗实体和液体肿瘤癌症以及与中性粒细胞驱动的炎症相关的疾病的治疗潜力。该实验药物是一流的抗微管蛋白药物，具有广谱抗癌活性和良好的药理学特性，包括临床试验的口服生物利用度。

BRG399 is leading the new oncology drug pipeline for BPGbio among other drug candidates which uniquely target the colchicine binding pocket in tubulin..

。。

About BPGbio

关于BPGbio

BPGbio is a leading biology-first AI-powered clinical stage biopharma focused on mitochondrial biology and protein homeostasis. The company has a deep pipeline of AI-developed therapeutics spanning oncology, rare disease and neurology, including several in late-stage clinical trials. BPGbio’s novel approach is underpinned by NAi, its proprietary Interrogative Biology Platform, protected by over 400 US and international patents; one of the world’s largest clinically annotated non-governmental biobanks with longitudinal samples; and exclusive access to the most powerful supercomputer in the world.

BPGbio是领先的生物学第一个AI支持的临床阶段生物制药，专注于线粒体生物学和蛋白质稳态。该公司拥有大量人工智能开发的治疗方法，涵盖肿瘤学，罕见病和神经病学，包括一些晚期临床试验。BPGbio的新方法得到了NAi的支持，NAi是其专有的询问生物学平台，受400多项美国和国际专利保护；世界上最大的临床注释非政府生物库之一，具有纵向样本；并独家访问世界上最强大的超级计算机。

With these tools, BPGbio is redefining how patient biology can be modeled using bespoke causal AI specifically designed for solving large-scale biology challenges. Headquartered in greater Boston, the company is at the forefront of a new era in medicine, combining biology, multi-modal data, and AI to transform the way we understand, diagnose, and treat diseases.

有了这些工具，BPGbio正在重新定义如何使用专门为解决大规模生物学挑战而设计的定制因果AI对患者生物学进行建模。该公司总部位于大波士顿，处于医学新时代的前沿，将生物学、多模式数据和人工智能相结合，改变我们理解、诊断和治疗疾病的方式。

For more information, visit www.bpgbio.com..

有关更多信息，请访问www.bpgbio.com。。